secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001787306-24-000078
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q1 product revenue $21.6M up 675% YoY; net loss narrows to $35.4M
-------------------------------------------------------------------------

- Q1 product revenue $21.6M ($15M cream, $6.5M foam) vs $2.8M in Q1 2023; 59% QoQ growth.
- Net loss $35.4M ($0.32/sh) vs $80.1M ($1.31/sh) in Q1 2023; cash $404.5M at March 31.
- PDUFA date July 7, 2024 for roflumilast cream 0.15% in atopic dermatitis (ages 6+).
- Completed $172.5M public offering in February; licensing deal with Sato Pharma for Japan.
- Appointed David Topper CFO effective April 10, 2024; sNDA for scalp/body psoriasis expected Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730624000078/0001787306-24-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730624000078/arqt-20240514.htm
  HTML page:      https://secwatch.observer/filing/0001787306-24-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer